Department of Surgery, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China.
Institute of Translational Medicine, Zhejiang University, Hangzhou 310009, China.
Theranostics. 2022 Mar 6;12(6):2658-2673. doi: 10.7150/thno.64244. eCollection 2022.
Chronic wounds are one of the common complications of diabetes. Due to the physiological conditions of diabetic patients, these wounds are more susceptible to bacterial infections and the formation of bacterial biofilms, leading to the inefficiency of conventional antibiotic treatment. Here, hollow mesoporous silica nanoparticles (HMSN) were used as the nanocarriers for co-delivery of azithromycin (AZM) and glucose oxidase (GOX), achieving a remarkable synergistic effect in chronic diabetic wounds. GOX possesses the catalytic ability to consume glucose and produce HO in the diabetic wound area. The down-regulation of local glucose could effectively improve the chronic diabetic wound microenvironment. Meanwhile, the generated HO effectively inhibits bacterial growth and eradicates bacterial biofilms with the synergism of antibiotics AZM. In the bacteria-infected diabetic cutaneous wound models, the reduction of glucose, generation of HO, and release of AZM could effectively reduce the bacterial infection and promote the wounds healing. Moreover, there is no obvious toxicity behavior after the treatment. Therefore, the designed nanosystem could effectively accelerate the diabetic wound healing process by the amelioration of the hyperglycemia microenvironment and the eradication of bacterial biofilms around the wounds, making them promising candidates for clinical transformation.
慢性创面是糖尿病的常见并发症之一。由于糖尿病患者的生理状况,这些创面更容易受到细菌感染和细菌生物膜的形成,导致传统抗生素治疗效果不佳。在这里,中空介孔硅纳米粒子(HMSN)被用作阿奇霉素(AZM)和葡萄糖氧化酶(GOX)的共递送纳米载体,在慢性糖尿病创面中实现了显著的协同作用。GOX 具有在糖尿病创面区域消耗葡萄糖并产生 HO 的催化能力。下调局部葡萄糖可以有效改善慢性糖尿病创面的微环境。同时,生成的 HO 与抗生素 AZM 协同作用,有效抑制细菌生长并根除细菌生物膜。在细菌感染的糖尿病皮肤创面模型中,葡萄糖的减少、HO 的产生和 AZM 的释放可以有效降低细菌感染并促进创面愈合。此外,治疗后没有明显的毒性行为。因此,所设计的纳米系统可以通过改善高血糖微环境和根除创面周围的细菌生物膜,有效加速糖尿病创面的愈合过程,有望成为临床转化的候选药物。